Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Clinical trial NCT06087263 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06087263
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-18
- Primary completion
- 2032-07-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.